PL2554541T3 - Środek terapeutyczny lub środek profilaktyczny na fibromialgię - Google Patents

Środek terapeutyczny lub środek profilaktyczny na fibromialgię

Info

Publication number
PL2554541T3
PL2554541T3 PL11765736T PL11765736T PL2554541T3 PL 2554541 T3 PL2554541 T3 PL 2554541T3 PL 11765736 T PL11765736 T PL 11765736T PL 11765736 T PL11765736 T PL 11765736T PL 2554541 T3 PL2554541 T3 PL 2554541T3
Authority
PL
Poland
Prior art keywords
agent
fibromyalgia
prophylactic
therapeutic agent
therapeutic
Prior art date
Application number
PL11765736T
Other languages
English (en)
Inventor
Chihiro Yoshida
Kaoru Nakao
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2554541T3 publication Critical patent/PL2554541T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL11765736T 2010-03-31 2011-03-31 Środek terapeutyczny lub środek profilaktyczny na fibromialgię PL2554541T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010083721 2010-03-31
EP11765736.1A EP2554541B1 (en) 2010-03-31 2011-03-31 Therapeutic agent or prophylactic agent for fibromyalgia
PCT/JP2011/058218 WO2011125836A1 (ja) 2010-03-31 2011-03-31 線維筋痛症の治療剤又は予防剤

Publications (1)

Publication Number Publication Date
PL2554541T3 true PL2554541T3 (pl) 2016-06-30

Family

ID=44762774

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11765736T PL2554541T3 (pl) 2010-03-31 2011-03-31 Środek terapeutyczny lub środek profilaktyczny na fibromialgię

Country Status (13)

Country Link
US (1) US8957094B2 (pl)
EP (1) EP2554541B1 (pl)
JP (1) JP5751168B2 (pl)
KR (1) KR101738471B1 (pl)
CN (1) CN102822148B (pl)
AU (1) AU2011237072B2 (pl)
BR (1) BR112012022947B1 (pl)
CA (1) CA2793709C (pl)
ES (1) ES2562470T3 (pl)
MX (1) MX2012010767A (pl)
PL (1) PL2554541T3 (pl)
RU (1) RU2560168C2 (pl)
WO (1) WO2011125836A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101739881B1 (ko) * 2010-04-28 2017-05-25 도레이 카부시키가이샤 알츠하이머병의 치료제 또는 예방제
RU2544552C2 (ru) * 2010-07-30 2015-03-20 Торэй Индастриз, Инк. Терапевтическое средство или профилактическое средство для нейропатической боли
JPWO2014088106A1 (ja) * 2012-12-06 2017-01-05 株式会社PRISM Pharma 線維筋痛症の予防または治療薬
WO2015115509A1 (ja) 2014-01-29 2015-08-06 東レ株式会社 多発性硬化症の治療剤又は予防剤
JP2018523705A (ja) * 2015-07-28 2018-08-23 ベータ・キャット・ファーマシューティカルズ・インコーポレイテッド アントラセン−9,10−ジオンジオキシム化合物プロドラッグ及びその使用
US11039755B2 (en) 2015-12-03 2021-06-22 Robert S. Katz Methods and systems for diagnosing and treating fibromyalgia
WO2018021508A1 (ja) * 2016-07-29 2018-02-01 日本たばこ産業株式会社 ピラゾール-アミド化合物の製造方法
WO2018181859A1 (ja) * 2017-03-31 2018-10-04 東レ株式会社 抗がん剤誘発末梢神経障害の治療剤又は予防剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
AU4308300A (en) 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
EP1545535A4 (en) * 2002-09-05 2008-06-04 Scios Inc TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE
CN101454299A (zh) 2006-03-27 2009-06-10 东丽株式会社 酰脲衍生物及其医药用途
EP2061775A2 (en) * 2006-09-13 2009-05-27 Astra Zeneca AB Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
US20080171762A1 (en) * 2007-01-16 2008-07-17 Ockert David M Treatment of pain with naloxone
WO2008105383A1 (ja) * 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途

Also Published As

Publication number Publication date
EP2554541A4 (en) 2013-10-09
JPWO2011125836A1 (ja) 2013-07-11
KR20130052536A (ko) 2013-05-22
CN102822148B (zh) 2015-03-11
ES2562470T3 (es) 2016-03-04
RU2560168C2 (ru) 2015-08-20
US8957094B2 (en) 2015-02-17
JP5751168B2 (ja) 2015-07-22
KR101738471B1 (ko) 2017-05-22
BR112012022947B1 (pt) 2021-06-15
WO2011125836A1 (ja) 2011-10-13
AU2011237072A1 (en) 2012-10-18
RU2012146325A (ru) 2014-05-10
CA2793709A1 (en) 2011-10-13
AU2011237072B2 (en) 2014-09-04
CA2793709C (en) 2017-09-12
US20130190503A1 (en) 2013-07-25
EP2554541B1 (en) 2015-12-09
EP2554541A1 (en) 2013-02-06
MX2012010767A (es) 2012-10-15
CN102822148A (zh) 2012-12-12
BR112012022947A2 (pt) 2020-07-28

Similar Documents

Publication Publication Date Title
SG10201506840QA (en) Cytotoxicity-inducing therapeutic agent
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
ZA201409186B (en) Therapeutic agent or prophylactic agent for dementia
EP2510949A4 (en) THERAPEUTICS FOR FIBROMYALGIA
PL2554541T3 (pl) Środek terapeutyczny lub środek profilaktyczny na fibromialgię
PL2529739T3 (pl) Środek terapeutyczny lub profilaktyczny na choroby dróg żółciowych
PL2723344T3 (pl) Złożony środek leczniczy zawierający monoterpen
IL245995B (en) Prophylactic or medical agent for fibrosis
IL220850A0 (en) Pigmentation-preventing or-ameliorating agent
PL2599487T3 (pl) Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu
GB201005394D0 (en) Therapy
ZA201206957B (en) Sterilising apparatus
GB201016864D0 (en) Therapeutic methods
ZA201303870B (en) Processes for the preparation of enamines
PL2646424T3 (pl) Sposób wytwarzania enamin
PL2637748T3 (pl) Armatura bezpieczeństwa
EP2629766A4 (en) COMBINATION THERAPY
IL226574A (en) Processes for making anamines
GB201003727D0 (en) Therapeutic agent
GB201011456D0 (en) Compositions and methods for embolization therapy
GB201018104D0 (en) Projection apparatus
GB201119761D0 (en) Examing procedure